Changchun High-Tech Industry Group Co

Changchun High-Tech Industry Group Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Changchun High-Tech Industry Group Co (000661.SZ) as of Nov 19, 2026 is 870.26 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 3.65 B CNY — a change of -76.17% (lower).

EBITDA

870.26 MCNY

YoY

-76.17%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Changchun High-Tech Industry Group Co is 2025 870.26 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Changchun High-Tech Industry Group Co was 2024 3.65 B CNY. It decreases by -76.17% lower compared to the previous year.

The Changchun High-Tech Industry Group Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
1.87 B CNY
Jan 1, 2019
2.95 B CNY
Jan 1, 2020
4.02 B CNY
Jan 1, 2021
4.89 B CNY
Jan 1, 2022
5.24 B CNY
Jan 1, 2023
5.88 B CNY
Jan 1, 2024
3.65 B CNY
Jan 1, 2025
870.26 M CNY
The Changchun High-Tech Industry Group Co EBITDA history
YEAREBITDAYoY
870.26 MCNY-76.17%
3.65 BCNY-37.86%
5.88 BCNY+12.17%
5.24 BCNY+7.12%
4.89 BCNY+21.81%
4.02 BCNY+36.27%
2.95 BCNY+57.42%
1.87 BCNY+58.52%
1.18 BCNY+41.57%
834.18 MCNY+28.78%
647.74 MCNY+14.13%
567.56 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Changchun High-Tech Industry Group Co Stock analysis

What does Changchun High-Tech Industry Group Co do? Changchun High & New Technology Industries (Group), Inc. generates revenue through the research, development, production, and sale of biopharmaceuticals and proprietary Chinese medicines. Key products include polyethylene glycol recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, freeze-dried live attenuated varicella vaccines, and rabies vaccines for human use. The company also derives income from real estate development and property management services. Its primary market is domestic, serving customers within China who require pharmaceutical solutions and real estate services. The firm's biopharmaceutical segment focuses on innovative treatments such as growth hormone therapies and vaccines, targeting healthcare providers and consumers seeking advanced medical solutions. Real estate activities involve developing and managing properties, catering to residential and commercial clients in the domestic market. All operations are conducted within China, with no international expansion mentioned in the business description. Changchun High & New Technology Industries (Group), Inc. leverages its 8,841 full-time employees to support both pharmaceutical and real estate divisions. The company's product portfolio emphasizes high-demand medical treatments, including injectable growth hormones and vaccines, which are sold to domestic healthcare institutions and end-users. Real estate services complement the core business by providing additional revenue streams through property management and development. Changchun High-Tech Industry Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Changchun High-Tech Industry Group Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Changchun High-Tech Industry Group Co is 870.26 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Changchun High-Tech Industry Group Co changed from 3.65 B CNY to 870.26 M CNY, representing a -76.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Changchun High-Tech Industry Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Changchun High-Tech Industry Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Changchun High-Tech Industry Group Co

All Key Metrics — Changchun High-Tech Industry Group Co